1. 1315PDevelopment and internal validation of a predictive nomogram of progression-free survival in well-differentiated stage IV gastroenteropancreatic neuroendocrine tumours treated with somatostatin analogues: GETNE-TRASGU study. (23rd October 2018) Authors: Garcia-Carbonero, R; Alonso, V; Capdevila, J; Sanchez Canovas, M; Alonso, T; Benavent, M; Custodio, A; Crespo Herrero, G; Lopez, C; Hernando, J; Riesco Martinez, M C; Escudero, P; Gallego Plazas, J; Marazuela, M; Diaz, J A; Llanos-Munoz, M; La Casta, A; Percovich, J C; Jimenez-Fonseca, P; Carmona... Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2033 Stage III colorectal cancer (CRC) in Spain: A retrospective analysis from 35 centres. (September 2015) Authors: Sotelo, L.; Sastre, J.; García-Paredes, B.; Cabezas-Camarero, S.; Vieitez, J.M.; Alonso, V.; Grávalos, C.; Escudero, P; Vera, R.; Aranda, E.; García-Alfonso, P.; Gallego-Plazas, J.; Lopez, C.; Pericay, C.; Arrivi, A.; Vicente, P; Ballesteros, P; Elez, E.; Lopez-Ladron, A.; Diaz-Rubio, E. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S339 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2128 Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD). (September 2015) Authors: Abad, A.; Massuti, B.; Gravalos, C.; Escudero, P; Guillen-Ponce, C.; Manzano, J.L.; Ortiz, M.J.; Safont, M.J.; Gallego, J.; Sastre, J.; Pericay, C.; Duenas, R.; Rivera, F.; Losa, F.; Valladares-Ayerbes, M.; Gonzalez, E.; Robles, L.; Aranda, E.; Carrato, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S374 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 478PIn the pathway to response: Is aflibercept an optimal treatment for RASwt mCRC patients after progression to 1st line containing anti-EGFR?. (23rd October 2018) Authors: Mata Velasco, E; González-Flores, E; Juez Martel, I; Alonso, V; Iranzo Gomez, P; Martinez Lago, N; Lopez, C; Cabrera Romero, J M; Safont Aguilera, M J; Ruiz Casado, A; Salgado Fernandez, M; González Astorga, B; Escudero, P; Rivera Herrero, F; Pericay Pijaume, C; Vera, R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 486PProspective biomarker study in advanced RAS wild-type colorectal cancer: POSIBA trial. (23rd October 2018) Authors: García Albéniz, X; Alonso, V; Escudero, P; Méndez, M; Gallego Plazas, J; Rodriguez, J R; Salud Salvia, A; Fernández-Plana, J; Manzano Alemany, H; Zanui, M; Falcó, E; Feliu Batlle, J; Gil-Raga, M; Fernández-Martos, C; Bohn Sarmiento, U; Alonso López, M C; Calderero Aragón, V; Rojo, F; Cuatrecasas,... Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 545PClinical impact of circulating tumor RAS and BRAF mutation dynamics in metastatic colorectal cancer patients treated with first-line chemotherapy plus anti-EGFR therapy: Combined analysis of two prospective clinical trials. (23rd October 2018) Authors: Montagut, C; Alonso, V; Escudero, P; Fernández-Martos, C; Salud Salvia, A; Méndez, M; Gallego Plazas, J; Rodriguez, J R; Martín-Richard, M; Fernández-Plana, J; Aparicio, J; Feliu Batlle, J; García de Albéniz, X; Rojo, F; Fernández, V; Claes, B; Maertens, G G; Sablon, E; Jacobs, B A W; Maurel, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 611TiPAVEVAC: A phase I-II trial with avelumab plus autologous dendritic cell (ADC) vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer (mCRC) patients (GEMCAD 16-02). (23rd October 2018) Authors: Español Rego, M; Alonso, V; Aparicio, J; Elez Fernandez, E; Escudero, P; Fernández-Martos, C; Rodríguez, N; Ruiz Casado, A; Cid, J; Cabezón, R; Lozano, M; Ginés, A; Bianchi, L; Garcia-Corbacho, J; García de Albéniz, X; Maurel, J; Benitez Ribas, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial. Issue 6 (May 2017) Authors: Pineda, Estela; Salud, A; Vila-Navarro, E; Safont, MJ; Llorente, Beatriz; Aparicio, J; Vera, R; Escudero, P; Casado, E; Bosch, C; Bohn, U; Pérez-Carrión, R; Carmona, A; Ayuso, JR; Ripollés, T; Bouzas, R; Gironella, M; García-Albéniz, X; Feliu, J; Maurel, J Journal: Tumor biology Issue: Volume 39:Issue 6(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗